| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 158 | 2024 | 2878 | 12.750 |
Why?
|
| Uric Acid | 40 | 2023 | 806 | 7.520 |
Why?
|
| Receptor, Adenosine A2A | 40 | 2020 | 128 | 5.350 |
Why?
|
| Neuroprotective Agents | 30 | 2023 | 957 | 4.890 |
Why?
|
| Caffeine | 32 | 2020 | 699 | 4.610 |
Why?
|
| Adenosine A2 Receptor Antagonists | 27 | 2020 | 49 | 4.190 |
Why?
|
| Antiparkinson Agents | 18 | 2024 | 184 | 3.270 |
Why?
|
| Parkinsonian Disorders | 12 | 2021 | 285 | 2.850 |
Why?
|
| Antioxidants | 12 | 2020 | 1669 | 2.170 |
Why?
|
| Inosine | 10 | 2023 | 129 | 1.820 |
Why?
|
| Purines | 15 | 2016 | 606 | 1.510 |
Why?
|
| Dopamine | 24 | 2023 | 1606 | 1.490 |
Why?
|
| Receptors, Purinergic P1 | 15 | 2003 | 108 | 1.360 |
Why?
|
| Corpus Striatum | 18 | 2020 | 1235 | 1.350 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 11 | 2017 | 89 | 1.270 |
Why?
|
| Dyskinesia, Drug-Induced | 6 | 2013 | 165 | 1.200 |
Why?
|
| Disease Progression | 21 | 2024 | 13495 | 1.200 |
Why?
|
| Astrocytes | 7 | 2018 | 1341 | 1.130 |
Why?
|
| Indans | 4 | 2010 | 92 | 1.030 |
Why?
|
| Levodopa | 11 | 2022 | 222 | 1.010 |
Why?
|
| REM Sleep Behavior Disorder | 7 | 2024 | 108 | 0.930 |
Why?
|
| Oxidative Stress | 7 | 2018 | 3115 | 0.930 |
Why?
|
| Amyotrophic Lateral Sclerosis | 9 | 2023 | 1462 | 0.910 |
Why?
|
| Monoamine Oxidase Inhibitors | 8 | 2010 | 155 | 0.880 |
Why?
|
| Receptor, Melanocortin, Type 1 | 4 | 2023 | 74 | 0.880 |
Why?
|
| Neurodegenerative Diseases | 4 | 2023 | 1085 | 0.840 |
Why?
|
| alpha-Synuclein | 11 | 2024 | 752 | 0.840 |
Why?
|
| Central Nervous System Stimulants | 9 | 2012 | 1177 | 0.830 |
Why?
|
| Oxidopamine | 11 | 2021 | 172 | 0.780 |
Why?
|
| Glucosylceramidase | 5 | 2024 | 128 | 0.780 |
Why?
|
| Parkinson Disease, Secondary | 7 | 2010 | 122 | 0.760 |
Why?
|
| Adenosine | 13 | 2020 | 805 | 0.730 |
Why?
|
| Substantia Nigra | 8 | 2018 | 350 | 0.730 |
Why?
|
| Neostriatum | 5 | 2017 | 247 | 0.720 |
Why?
|
| Urate Oxidase | 4 | 2012 | 31 | 0.720 |
Why?
|
| Purinergic P1 Receptor Antagonists | 8 | 2010 | 45 | 0.700 |
Why?
|
| Alkaloids | 2 | 2020 | 192 | 0.680 |
Why?
|
| Clinical Trials as Topic | 12 | 2024 | 7995 | 0.680 |
Why?
|
| Receptors, Metabotropic Glutamate | 4 | 2010 | 195 | 0.660 |
Why?
|
| MPTP Poisoning | 3 | 2017 | 37 | 0.650 |
Why?
|
| Prosencephalon | 4 | 2016 | 305 | 0.640 |
Why?
|
| Motor Activity | 15 | 2018 | 2714 | 0.620 |
Why?
|
| Drug Repositioning | 1 | 2020 | 233 | 0.620 |
Why?
|
| Mice, Inbred C57BL | 43 | 2023 | 22117 | 0.610 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 8 | 2022 | 415 | 0.600 |
Why?
|
| Huntington Disease | 2 | 2022 | 1144 | 0.590 |
Why?
|
| Dopamine Agents | 4 | 2003 | 189 | 0.570 |
Why?
|
| Cytoprotection | 2 | 2010 | 200 | 0.560 |
Why?
|
| Pigmentation | 1 | 2017 | 144 | 0.530 |
Why?
|
| Receptor, Adenosine A1 | 3 | 2010 | 42 | 0.520 |
Why?
|
| Theophylline | 2 | 2020 | 131 | 0.520 |
Why?
|
| Sex Characteristics | 7 | 2020 | 2637 | 0.520 |
Why?
|
| Animals | 92 | 2023 | 168202 | 0.510 |
Why?
|
| Disease Models, Animal | 25 | 2023 | 18220 | 0.500 |
Why?
|
| Mice, Knockout | 34 | 2021 | 14388 | 0.480 |
Why?
|
| Mice | 66 | 2023 | 81368 | 0.480 |
Why?
|
| Amphetamine | 3 | 2005 | 224 | 0.470 |
Why?
|
| Maneb | 2 | 2014 | 3 | 0.470 |
Why?
|
| Paraquat | 2 | 2014 | 32 | 0.470 |
Why?
|
| Humans | 182 | 2024 | 760740 | 0.450 |
Why?
|
| Constipation | 5 | 2021 | 563 | 0.450 |
Why?
|
| Risk | 18 | 2022 | 9603 | 0.430 |
Why?
|
| Gout | 2 | 2018 | 621 | 0.430 |
Why?
|
| Pesticides | 2 | 2014 | 296 | 0.430 |
Why?
|
| Motor Neurons | 1 | 2018 | 869 | 0.420 |
Why?
|
| Restless Legs Syndrome | 5 | 2018 | 233 | 0.420 |
Why?
|
| Flavonoids | 3 | 2024 | 445 | 0.420 |
Why?
|
| Glutathione | 1 | 2015 | 582 | 0.420 |
Why?
|
| Xanthines | 8 | 2020 | 120 | 0.420 |
Why?
|
| Behavior, Animal | 6 | 2017 | 1872 | 0.420 |
Why?
|
| Allopurinol | 1 | 2014 | 198 | 0.410 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 2012 | 1540 | 0.400 |
Why?
|
| Male | 135 | 2024 | 360402 | 0.390 |
Why?
|
| Neurons | 16 | 2012 | 9436 | 0.390 |
Why?
|
| Receptors, Adenosine A2 | 6 | 2009 | 14 | 0.380 |
Why?
|
| Alzheimer Disease | 6 | 2023 | 8603 | 0.370 |
Why?
|
| Drug Discovery | 2 | 2021 | 1051 | 0.370 |
Why?
|
| Basal Ganglia | 3 | 2009 | 554 | 0.370 |
Why?
|
| Life Style | 4 | 2019 | 3907 | 0.360 |
Why?
|
| Tyrosine 3-Monooxygenase | 9 | 2009 | 370 | 0.360 |
Why?
|
| Nerve Degeneration | 3 | 2021 | 747 | 0.360 |
Why?
|
| Lewy Body Disease | 1 | 2013 | 254 | 0.350 |
Why?
|
| Drug Evaluation, Preclinical | 3 | 2015 | 1333 | 0.350 |
Why?
|
| Heterozygote | 4 | 2022 | 2780 | 0.350 |
Why?
|
| Culture Media, Conditioned | 3 | 2018 | 522 | 0.340 |
Why?
|
| Glutamic Acid | 5 | 2012 | 1175 | 0.340 |
Why?
|
| Nerve Tissue Proteins | 9 | 2012 | 4408 | 0.340 |
Why?
|
| Receptors, Dopamine D2 | 6 | 2009 | 484 | 0.330 |
Why?
|
| Neurotoxins | 2 | 2017 | 240 | 0.310 |
Why?
|
| Brain | 11 | 2019 | 27100 | 0.310 |
Why?
|
| Probability | 2 | 2023 | 2475 | 0.290 |
Why?
|
| Enzyme Inhibitors | 5 | 2014 | 3705 | 0.290 |
Why?
|
| Mice, Transgenic | 9 | 2021 | 9526 | 0.280 |
Why?
|
| Nicotine | 2 | 2024 | 679 | 0.280 |
Why?
|
| Female | 101 | 2024 | 392203 | 0.280 |
Why?
|
| Follow-Up Studies | 34 | 2023 | 39062 | 0.280 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 489 | 0.280 |
Why?
|
| Aged | 69 | 2024 | 169092 | 0.270 |
Why?
|
| Mutation | 8 | 2022 | 30015 | 0.270 |
Why?
|
| Glucose Transport Proteins, Facilitative | 2 | 2018 | 57 | 0.270 |
Why?
|
| Research Design | 6 | 2024 | 6174 | 0.270 |
Why?
|
| Drug Interactions | 7 | 2010 | 1415 | 0.270 |
Why?
|
| NF-E2-Related Factor 2 | 3 | 2023 | 373 | 0.260 |
Why?
|
| Middle Aged | 79 | 2024 | 220603 | 0.260 |
Why?
|
| Cohort Studies | 34 | 2022 | 41464 | 0.260 |
Why?
|
| Mesencephalon | 2 | 2012 | 333 | 0.250 |
Why?
|
| Cells, Cultured | 13 | 2018 | 18937 | 0.250 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2013 | 10754 | 0.250 |
Why?
|
| Genetic Counseling | 3 | 2024 | 627 | 0.240 |
Why?
|
| Cytochrome P-450 CYP1A2 | 3 | 2018 | 69 | 0.240 |
Why?
|
| Case-Control Studies | 18 | 2023 | 22153 | 0.240 |
Why?
|
| Gene Deletion | 1 | 2012 | 2659 | 0.230 |
Why?
|
| Nitrites | 3 | 2014 | 159 | 0.230 |
Why?
|
| Drug Tolerance | 2 | 2003 | 367 | 0.220 |
Why?
|
| Protein Carbonylation | 2 | 2014 | 28 | 0.220 |
Why?
|
| Benzothiazoles | 2 | 2016 | 247 | 0.220 |
Why?
|
| Analysis of Variance | 6 | 2013 | 6223 | 0.220 |
Why?
|
| Risk Factors | 48 | 2024 | 74128 | 0.220 |
Why?
|
| Proportional Hazards Models | 23 | 2024 | 12448 | 0.220 |
Why?
|
| Parasomnias | 1 | 2023 | 27 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-jun | 2 | 2001 | 287 | 0.220 |
Why?
|
| Diet | 12 | 2024 | 8049 | 0.220 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 6 | 2020 | 2270 | 0.210 |
Why?
|
| Central Nervous System Diseases | 1 | 2007 | 521 | 0.210 |
Why?
|
| Estrogen Replacement Therapy | 3 | 2010 | 1208 | 0.210 |
Why?
|
| Smoking | 16 | 2024 | 9054 | 0.210 |
Why?
|
| Dopamine Agonists | 5 | 2006 | 352 | 0.190 |
Why?
|
| Genetic Testing | 4 | 2024 | 3533 | 0.190 |
Why?
|
| Eating | 2 | 2020 | 1535 | 0.190 |
Why?
|
| Vasoactive Intestinal Peptide | 3 | 1994 | 179 | 0.190 |
Why?
|
| Somnambulism | 1 | 2021 | 13 | 0.190 |
Why?
|
| Armadillo Domain Proteins | 1 | 2021 | 24 | 0.190 |
Why?
|
| Cyclic AMP | 4 | 2016 | 1463 | 0.190 |
Why?
|
| Pyrimidines | 6 | 2021 | 3027 | 0.180 |
Why?
|
| Rats | 20 | 2017 | 23716 | 0.180 |
Why?
|
| Sex Factors | 8 | 2020 | 10549 | 0.180 |
Why?
|
| Phenethylamines | 8 | 2008 | 95 | 0.180 |
Why?
|
| Exercise | 7 | 2023 | 5886 | 0.180 |
Why?
|
| Secretin | 2 | 1991 | 57 | 0.170 |
Why?
|
| Hydrogen Peroxide | 2 | 2014 | 730 | 0.170 |
Why?
|
| Iron Chelating Agents | 1 | 2020 | 138 | 0.170 |
Why?
|
| Chromatography, Liquid | 2 | 2020 | 982 | 0.170 |
Why?
|
| Folic Acid | 2 | 2023 | 1323 | 0.170 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2023 | 301 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2024 | 10203 | 0.170 |
Why?
|
| Dairy Products | 2 | 2017 | 490 | 0.170 |
Why?
|
| Brain Injury, Chronic | 1 | 1999 | 68 | 0.160 |
Why?
|
| Coculture Techniques | 2 | 2014 | 1336 | 0.160 |
Why?
|
| Drug Delivery Systems | 2 | 2011 | 2222 | 0.160 |
Why?
|
| Ibuprofen | 3 | 2012 | 229 | 0.160 |
Why?
|
| Olfaction Disorders | 2 | 2018 | 224 | 0.160 |
Why?
|
| Receptors, Dopamine D1 | 5 | 2009 | 292 | 0.160 |
Why?
|
| Blotting, Western | 8 | 2012 | 5034 | 0.160 |
Why?
|
| Locomotion | 3 | 2010 | 388 | 0.160 |
Why?
|
| Animals, Newborn | 5 | 2012 | 2669 | 0.160 |
Why?
|
| Penetrance | 1 | 2020 | 382 | 0.160 |
Why?
|
| Prospective Studies | 32 | 2024 | 54364 | 0.160 |
Why?
|
| Coffee | 5 | 2012 | 592 | 0.160 |
Why?
|
| Estradiol | 1 | 2006 | 1937 | 0.160 |
Why?
|
| Benzamides | 2 | 2015 | 1371 | 0.160 |
Why?
|
| Videoconferencing | 1 | 2020 | 203 | 0.150 |
Why?
|
| Dynorphins | 3 | 2010 | 82 | 0.150 |
Why?
|
| Triazoles | 9 | 2009 | 903 | 0.150 |
Why?
|
| DNA, Mitochondrial | 2 | 2023 | 865 | 0.150 |
Why?
|
| Adult | 51 | 2024 | 220995 | 0.150 |
Why?
|
| Double-Blind Method | 9 | 2023 | 12333 | 0.140 |
Why?
|
| Secondary Prevention | 1 | 2024 | 1470 | 0.140 |
Why?
|
| Tremor | 2 | 2022 | 190 | 0.140 |
Why?
|
| Phosphoproteins | 2 | 2004 | 2445 | 0.140 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2018 | 894 | 0.140 |
Why?
|
| Membrane Glycoproteins | 3 | 2002 | 3688 | 0.140 |
Why?
|
| Sympathetic Nervous System | 2 | 1991 | 519 | 0.140 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2018 | 214 | 0.140 |
Why?
|
| Signal Transduction | 7 | 2017 | 23415 | 0.140 |
Why?
|
| Contraceptives, Oral, Hormonal | 2 | 2017 | 190 | 0.140 |
Why?
|
| Purinergic P1 Receptor Agonists | 5 | 2003 | 39 | 0.140 |
Why?
|
| Dementia | 3 | 2023 | 2686 | 0.140 |
Why?
|
| Lymphokines | 2 | 2002 | 925 | 0.140 |
Why?
|
| Metabolomics | 3 | 2020 | 1656 | 0.130 |
Why?
|
| Exercise Therapy | 2 | 2022 | 929 | 0.130 |
Why?
|
| Enkephalins | 2 | 2010 | 139 | 0.130 |
Why?
|
| Environmental Exposure | 3 | 2017 | 4483 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2024 | 17878 | 0.130 |
Why?
|
| Mass Spectrometry | 2 | 2020 | 2189 | 0.130 |
Why?
|
| Hydrocephalus, Normal Pressure | 1 | 1997 | 99 | 0.130 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2018 | 269 | 0.130 |
Why?
|
| Hair Color | 2 | 2023 | 131 | 0.130 |
Why?
|
| Cell Line | 5 | 2018 | 15577 | 0.130 |
Why?
|
| Movement Disorders | 2 | 2003 | 459 | 0.130 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 3 | 2006 | 63 | 0.130 |
Why?
|
| Tropanes | 2 | 2015 | 48 | 0.130 |
Why?
|
| Transcription Factor AP-1 | 1 | 1997 | 319 | 0.130 |
Why?
|
| Self Efficacy | 1 | 2020 | 636 | 0.130 |
Why?
|
| Monoamine Oxidase | 3 | 2009 | 181 | 0.130 |
Why?
|
| Cytoskeletal Proteins | 1 | 2021 | 1336 | 0.120 |
Why?
|
| Synapses | 2 | 2021 | 1754 | 0.120 |
Why?
|
| Erectile Dysfunction | 2 | 2010 | 444 | 0.120 |
Why?
|
| Mice, 129 Strain | 1 | 2016 | 370 | 0.120 |
Why?
|
| Longitudinal Studies | 9 | 2022 | 14599 | 0.120 |
Why?
|
| Melanoma | 3 | 2023 | 5696 | 0.120 |
Why?
|
| Superior Cervical Ganglion | 1 | 1994 | 33 | 0.120 |
Why?
|
| Labor, Obstetric | 1 | 1998 | 323 | 0.120 |
Why?
|
| Appendectomy | 1 | 2018 | 433 | 0.120 |
Why?
|
| Toxoplasmosis, Cerebral | 1 | 1994 | 19 | 0.120 |
Why?
|
| Incidence | 15 | 2023 | 21339 | 0.120 |
Why?
|
| RNA, Messenger | 10 | 2015 | 12759 | 0.120 |
Why?
|
| Sirtuin 2 | 1 | 2015 | 94 | 0.120 |
Why?
|
| Feeding Behavior | 2 | 2020 | 3183 | 0.120 |
Why?
|
| Vitamin E | 2 | 2016 | 872 | 0.110 |
Why?
|
| Ischemic Attack, Transient | 1 | 1999 | 874 | 0.110 |
Why?
|
| Cell Survival | 3 | 2014 | 5780 | 0.110 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2015 | 433 | 0.110 |
Why?
|
| Free Radicals | 1 | 2014 | 238 | 0.110 |
Why?
|
| Treatment Outcome | 9 | 2023 | 64572 | 0.110 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2023 | 1390 | 0.110 |
Why?
|
| Xanthine | 1 | 2013 | 11 | 0.110 |
Why?
|
| Carotenoids | 1 | 2016 | 621 | 0.110 |
Why?
|
| Motivation | 2 | 2021 | 2003 | 0.110 |
Why?
|
| Allantoin | 1 | 2012 | 3 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2000 | 1242 | 0.110 |
Why?
|
| Growth Inhibitors | 1 | 1994 | 375 | 0.110 |
Why?
|
| Ascorbic Acid | 1 | 2016 | 655 | 0.110 |
Why?
|
| Cell Count | 3 | 2018 | 1834 | 0.110 |
Why?
|
| Postmortem Changes | 1 | 2013 | 119 | 0.110 |
Why?
|
| Axons | 1 | 2021 | 1671 | 0.110 |
Why?
|
| Dominance, Cerebral | 1 | 1994 | 623 | 0.100 |
Why?
|
| Metals, Heavy | 1 | 2014 | 148 | 0.100 |
Why?
|
| Multifactorial Inheritance | 1 | 2021 | 1381 | 0.100 |
Why?
|
| Nerve Endings | 2 | 1991 | 105 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2021 | 2425 | 0.100 |
Why?
|
| Protein Multimerization | 1 | 2018 | 982 | 0.100 |
Why?
|
| Tetanus Toxin | 2 | 2004 | 45 | 0.100 |
Why?
|
| 1-Methyl-4-phenylpyridinium | 1 | 2012 | 34 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2018 | 15908 | 0.100 |
Why?
|
| Anxiety | 1 | 2007 | 4573 | 0.100 |
Why?
|
| Cerebral Cortex | 4 | 2015 | 5776 | 0.100 |
Why?
|
| Synaptic Transmission | 2 | 2009 | 1169 | 0.100 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2012 | 201 | 0.100 |
Why?
|
| Alcohol Drinking | 6 | 2020 | 4028 | 0.100 |
Why?
|
| Air Pollutants | 3 | 2017 | 2893 | 0.100 |
Why?
|
| N-Methylaspartate | 2 | 2005 | 230 | 0.100 |
Why?
|
| Ganglia, Sympathetic | 2 | 1989 | 65 | 0.100 |
Why?
|
| Canada | 3 | 2024 | 2120 | 0.100 |
Why?
|
| Theobromine | 2 | 2002 | 14 | 0.100 |
Why?
|
| Stroke | 1 | 2014 | 9715 | 0.100 |
Why?
|
| Metabolome | 1 | 2019 | 988 | 0.100 |
Why?
|
| Air Pollution | 2 | 2017 | 2355 | 0.100 |
Why?
|
| Oxidants | 1 | 2012 | 169 | 0.100 |
Why?
|
| Diabetes Mellitus | 4 | 2020 | 5838 | 0.100 |
Why?
|
| Electrochemical Techniques | 1 | 2012 | 93 | 0.100 |
Why?
|
| Genetic Loci | 1 | 2021 | 2624 | 0.100 |
Why?
|
| Aged, 80 and over | 17 | 2021 | 58919 | 0.090 |
Why?
|
| Severity of Illness Index | 9 | 2022 | 15829 | 0.090 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2022 | 602 | 0.090 |
Why?
|
| Thiazoles | 1 | 2018 | 1517 | 0.090 |
Why?
|
| Cardiovascular System | 1 | 2018 | 834 | 0.090 |
Why?
|
| Tissue Culture Techniques | 1 | 2012 | 289 | 0.090 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2014 | 424 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 1810 | 0.090 |
Why?
|
| Molecular Imaging | 1 | 2018 | 814 | 0.090 |
Why?
|
| United States | 21 | 2024 | 72292 | 0.090 |
Why?
|
| Time Factors | 11 | 2012 | 39908 | 0.090 |
Why?
|
| Gene Expression Regulation | 6 | 2015 | 11874 | 0.090 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1994 | 662 | 0.090 |
Why?
|
| Genetic Variation | 3 | 2024 | 6561 | 0.090 |
Why?
|
| Fungicides, Industrial | 1 | 2010 | 13 | 0.090 |
Why?
|
| Adrenergic Agents | 1 | 2010 | 74 | 0.090 |
Why?
|
| Particle Size | 1 | 2014 | 1648 | 0.090 |
Why?
|
| Drug Administration Schedule | 3 | 2010 | 4845 | 0.090 |
Why?
|
| Neurologic Examination | 3 | 2020 | 915 | 0.090 |
Why?
|
| Gene Expression | 7 | 2018 | 7569 | 0.080 |
Why?
|
| Gliosis | 2 | 2018 | 245 | 0.080 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2012 | 1068 | 0.080 |
Why?
|
| Cyclic GMP | 1 | 1991 | 395 | 0.080 |
Why?
|
| Nurses | 7 | 2016 | 2477 | 0.080 |
Why?
|
| Odds Ratio | 5 | 2018 | 9644 | 0.080 |
Why?
|
| Immunohistochemistry | 6 | 2012 | 11069 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2020 | 2688 | 0.080 |
Why?
|
| Microglia | 3 | 2023 | 1357 | 0.080 |
Why?
|
| Cerebrovascular Circulation | 1 | 1999 | 2726 | 0.080 |
Why?
|
| Herbicides | 1 | 2010 | 105 | 0.080 |
Why?
|
| Genetic Determinism | 1 | 2009 | 10 | 0.080 |
Why?
|
| Small Molecule Libraries | 1 | 2015 | 733 | 0.080 |
Why?
|
| Dopamine Uptake Inhibitors | 2 | 2002 | 297 | 0.080 |
Why?
|
| ras Proteins | 1 | 1994 | 1054 | 0.080 |
Why?
|
| Hemodynamics | 1 | 1999 | 4160 | 0.080 |
Why?
|
| Beverages | 5 | 2017 | 821 | 0.080 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2014 | 1007 | 0.080 |
Why?
|
| Neuroglia | 2 | 2012 | 954 | 0.080 |
Why?
|
| Language | 1 | 1998 | 1541 | 0.080 |
Why?
|
| Adenosine A1 Receptor Antagonists | 2 | 2008 | 27 | 0.080 |
Why?
|
| Cholecalciferol | 1 | 2013 | 553 | 0.080 |
Why?
|
| Lipopolysaccharides | 4 | 2023 | 2202 | 0.080 |
Why?
|
| Reproductive History | 1 | 2009 | 210 | 0.080 |
Why?
|
| Phosphorylation | 7 | 2009 | 8311 | 0.070 |
Why?
|
| Cognition Disorders | 4 | 2021 | 3979 | 0.070 |
Why?
|
| Genotype | 7 | 2018 | 12977 | 0.070 |
Why?
|
| Anthocyanins | 2 | 2022 | 80 | 0.070 |
Why?
|
| Calcium | 2 | 1999 | 5717 | 0.070 |
Why?
|
| Growth Hormone-Releasing Hormone | 1 | 1989 | 128 | 0.070 |
Why?
|
| Indoles | 2 | 2014 | 1830 | 0.070 |
Why?
|
| Recreation | 1 | 2008 | 125 | 0.070 |
Why?
|
| Cross-Sectional Studies | 5 | 2021 | 26065 | 0.070 |
Why?
|
| Calcium Channel Blockers | 1 | 2010 | 694 | 0.070 |
Why?
|
| Health Surveys | 5 | 2018 | 4036 | 0.070 |
Why?
|
| Cognition | 2 | 2023 | 6988 | 0.070 |
Why?
|
| Autoradiography | 2 | 2005 | 728 | 0.070 |
Why?
|
| Triazines | 5 | 2007 | 311 | 0.070 |
Why?
|
| Scleroderma, Diffuse | 1 | 2006 | 18 | 0.070 |
Why?
|
| Dopamine and cAMP-Regulated Phosphoprotein 32 | 2 | 2004 | 29 | 0.070 |
Why?
|
| Causality | 3 | 2021 | 1241 | 0.070 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2006 | 446 | 0.070 |
Why?
|
| Particulate Matter | 2 | 2017 | 2602 | 0.070 |
Why?
|
| Nutritional Status | 3 | 2012 | 1597 | 0.070 |
Why?
|
| Protein Phosphatase 2 | 1 | 2008 | 231 | 0.070 |
Why?
|
| Blood Pressure | 2 | 2018 | 8473 | 0.070 |
Why?
|
| Protein Precursors | 1 | 2010 | 1131 | 0.070 |
Why?
|
| 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 1 | 2005 | 54 | 0.060 |
Why?
|
| Drug Synergism | 2 | 2005 | 1756 | 0.060 |
Why?
|
| Radioligand Assay | 2 | 2005 | 366 | 0.060 |
Why?
|
| Insulin Resistance | 1 | 2020 | 3954 | 0.060 |
Why?
|
| Injections, Intraperitoneal | 2 | 2008 | 412 | 0.060 |
Why?
|
| Health Personnel | 5 | 2016 | 3333 | 0.060 |
Why?
|
| Early Growth Response Protein 2 | 1 | 2005 | 25 | 0.060 |
Why?
|
| Movement | 1 | 2012 | 1476 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2013 | 6339 | 0.060 |
Why?
|
| Tritium | 2 | 2005 | 706 | 0.060 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 2 | 1999 | 502 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2006 | 4569 | 0.060 |
Why?
|
| Attitude to Health | 2 | 2020 | 2025 | 0.060 |
Why?
|
| Age Factors | 8 | 2012 | 18381 | 0.060 |
Why?
|
| Drug Implants | 1 | 2006 | 230 | 0.060 |
Why?
|
| Vitamin B 6 | 2 | 2023 | 234 | 0.060 |
Why?
|
| Rats, Inbred Strains | 4 | 1991 | 2088 | 0.060 |
Why?
|
| Wine | 3 | 2012 | 166 | 0.060 |
Why?
|
| Kinetics | 3 | 2003 | 6370 | 0.060 |
Why?
|
| Dermis | 1 | 2006 | 202 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2015 | 1977 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2007 | 4340 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 2851 | 0.060 |
Why?
|
| Hypercholesterolemia | 2 | 2012 | 1141 | 0.060 |
Why?
|
| Reactive Oxygen Species | 1 | 2012 | 2137 | 0.060 |
Why?
|
| Macrophages, Peritoneal | 2 | 2002 | 238 | 0.060 |
Why?
|
| Brain Injuries | 1 | 2016 | 2053 | 0.060 |
Why?
|
| Hippocampus | 2 | 2007 | 3762 | 0.060 |
Why?
|
| Rotenone | 1 | 2023 | 45 | 0.060 |
Why?
|
| Fruit | 2 | 2024 | 1158 | 0.060 |
Why?
|
| Genomic Library | 2 | 2004 | 189 | 0.060 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 1388 | 0.060 |
Why?
|
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2023 | 23 | 0.060 |
Why?
|
| Early Diagnosis | 2 | 2022 | 1185 | 0.060 |
Why?
|
| Awareness | 1 | 2008 | 649 | 0.060 |
Why?
|
| Peptides | 3 | 1994 | 4354 | 0.060 |
Why?
|
| Logistic Models | 5 | 2020 | 13248 | 0.050 |
Why?
|
| Protein Sorting Signals | 1 | 2004 | 278 | 0.050 |
Why?
|
| Pesticide Residues | 1 | 2024 | 95 | 0.050 |
Why?
|
| Vitamin B 12 | 2 | 2023 | 524 | 0.050 |
Why?
|
| Ovariectomy | 1 | 2006 | 613 | 0.050 |
Why?
|
| Genome-Wide Association Study | 2 | 2021 | 12661 | 0.050 |
Why?
|
| C-Reactive Protein | 2 | 2022 | 3820 | 0.050 |
Why?
|
| Postural Balance | 1 | 2008 | 622 | 0.050 |
Why?
|
| Propionates | 1 | 2004 | 183 | 0.050 |
Why?
|
| Telemedicine | 1 | 2020 | 3051 | 0.050 |
Why?
|
| Methylation | 1 | 2006 | 1077 | 0.050 |
Why?
|
| Adenosine A2 Receptor Agonists | 3 | 2008 | 30 | 0.050 |
Why?
|
| Mazindol | 1 | 2002 | 13 | 0.050 |
Why?
|
| Estrogens | 1 | 2009 | 1521 | 0.050 |
Why?
|
| Interleukin-6 | 2 | 2007 | 3205 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2010 | 1626 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 6520 | 0.050 |
Why?
|
| Environment | 1 | 2008 | 1123 | 0.050 |
Why?
|
| Cholesterol | 1 | 2011 | 2902 | 0.050 |
Why?
|
| Excitatory Postsynaptic Potentials | 3 | 2009 | 369 | 0.050 |
Why?
|
| Cacao | 1 | 2003 | 98 | 0.050 |
Why?
|
| Body Temperature | 2 | 2008 | 780 | 0.050 |
Why?
|
| Obesity | 3 | 2011 | 12934 | 0.050 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2023 | 225 | 0.050 |
Why?
|
| Work Schedule Tolerance | 1 | 2006 | 552 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2010 | 2208 | 0.050 |
Why?
|
| Survival Analysis | 4 | 2021 | 10072 | 0.050 |
Why?
|
| Vesicular Transport Proteins | 1 | 2024 | 376 | 0.050 |
Why?
|
| Superoxide Dismutase | 1 | 2004 | 593 | 0.050 |
Why?
|
| Telomere | 1 | 2008 | 942 | 0.050 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2023 | 242 | 0.050 |
Why?
|
| Retrospective Studies | 11 | 2023 | 80583 | 0.050 |
Why?
|
| Catalepsy | 1 | 2001 | 31 | 0.050 |
Why?
|
| Catechols | 1 | 2001 | 62 | 0.050 |
Why?
|
| Cocaine | 2 | 2012 | 958 | 0.050 |
Why?
|
| Brain Ischemia | 1 | 2015 | 3030 | 0.050 |
Why?
|
| Rats, Wistar | 3 | 2012 | 1848 | 0.050 |
Why?
|
| Central Nervous System | 2 | 2009 | 1333 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2008 | 1505 | 0.050 |
Why?
|
| Activities of Daily Living | 2 | 2023 | 2419 | 0.050 |
Why?
|
| Cloning, Molecular | 2 | 2004 | 4172 | 0.050 |
Why?
|
| North America | 1 | 2024 | 1273 | 0.040 |
Why?
|
| Phobic Disorders | 1 | 2003 | 439 | 0.040 |
Why?
|
| Hypertension | 3 | 2010 | 8532 | 0.040 |
Why?
|
| Feedback, Physiological | 1 | 2003 | 475 | 0.040 |
Why?
|
| Amphetamines | 1 | 2001 | 143 | 0.040 |
Why?
|
| Palatal Neoplasms | 1 | 2000 | 37 | 0.040 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2023 | 540 | 0.040 |
Why?
|
| Dopamine Antagonists | 1 | 2001 | 288 | 0.040 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 673 | 0.040 |
Why?
|
| Peptide Fragments | 2 | 2004 | 5109 | 0.040 |
Why?
|
| Metagenomics | 1 | 2023 | 463 | 0.040 |
Why?
|
| Palate | 1 | 2000 | 125 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2012 | 14649 | 0.040 |
Why?
|
| Membrane Transport Proteins | 2 | 2002 | 1034 | 0.040 |
Why?
|
| Binding Sites | 3 | 2005 | 6051 | 0.040 |
Why?
|
| Genetic Vectors | 2 | 2018 | 3392 | 0.040 |
Why?
|
| Egtazic Acid | 1 | 1999 | 167 | 0.040 |
Why?
|
| Diphtheria Toxin | 1 | 2000 | 253 | 0.040 |
Why?
|
| Arousal | 1 | 2005 | 1171 | 0.040 |
Why?
|
| Haloperidol | 1 | 2001 | 389 | 0.040 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2001 | 195 | 0.040 |
Why?
|
| Fibrosis | 1 | 2006 | 2047 | 0.040 |
Why?
|
| Nitric Oxide | 2 | 2005 | 2135 | 0.040 |
Why?
|
| Sleep Deprivation | 1 | 2006 | 847 | 0.040 |
Why?
|
| Dependovirus | 2 | 2018 | 712 | 0.040 |
Why?
|
| Physical Fitness | 1 | 2023 | 743 | 0.040 |
Why?
|
| Environmental Pollutants | 1 | 2008 | 1277 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2008 | 3591 | 0.040 |
Why?
|
| Acetaminophen | 3 | 2011 | 555 | 0.040 |
Why?
|
| Vegetables | 1 | 2024 | 1192 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2018 | 2467 | 0.040 |
Why?
|
| Carnitine | 1 | 2020 | 252 | 0.040 |
Why?
|
| Disclosure | 1 | 2024 | 747 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 857 | 0.040 |
Why?
|
| Protein Kinases | 2 | 2024 | 1606 | 0.040 |
Why?
|
| Age of Onset | 2 | 2003 | 3303 | 0.040 |
Why?
|
| Predictive Value of Tests | 3 | 2011 | 15250 | 0.040 |
Why?
|
| Parents | 2 | 2010 | 3563 | 0.040 |
Why?
|
| Beer | 2 | 2012 | 134 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2014 | 8165 | 0.040 |
Why?
|
| Models, Neurological | 1 | 2006 | 1768 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 4242 | 0.040 |
Why?
|
| Aspartic Acid | 2 | 2012 | 576 | 0.040 |
Why?
|
| Protein Kinase C | 2 | 1994 | 1202 | 0.040 |
Why?
|
| Embryo, Mammalian | 2 | 2005 | 1670 | 0.040 |
Why?
|
| Exons | 1 | 2004 | 2381 | 0.040 |
Why?
|
| Interleukin-12 | 1 | 2000 | 577 | 0.040 |
Why?
|
| Transcription, Genetic | 2 | 2005 | 7583 | 0.040 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2010 | 2518 | 0.040 |
Why?
|
| Phenotype | 5 | 2018 | 16572 | 0.040 |
Why?
|
| Gene Order | 1 | 2018 | 169 | 0.040 |
Why?
|
| Benzimidazoles | 1 | 2003 | 858 | 0.040 |
Why?
|
| Immunity | 1 | 2023 | 994 | 0.040 |
Why?
|
| Activating Transcription Factor 2 | 1 | 1997 | 44 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 1700 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2004 | 1503 | 0.040 |
Why?
|
| Colorimetry | 1 | 2017 | 150 | 0.040 |
Why?
|
| Leucine Zippers | 1 | 1997 | 116 | 0.040 |
Why?
|
| Kidney Calculi | 1 | 2021 | 463 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2005 | 4117 | 0.030 |
Why?
|
| Radiography | 1 | 2008 | 6961 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 3245 | 0.030 |
Why?
|
| Pyridines | 2 | 2005 | 2875 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 2005 | 1882 | 0.030 |
Why?
|
| Reperfusion Injury | 1 | 2003 | 1023 | 0.030 |
Why?
|
| Apolipoprotein E4 | 1 | 2021 | 709 | 0.030 |
Why?
|
| Haplotypes | 1 | 2023 | 2713 | 0.030 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 1 | 1997 | 93 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2001 | 1217 | 0.030 |
Why?
|
| Plasma | 1 | 2020 | 586 | 0.030 |
Why?
|
| Body Mass Index | 6 | 2011 | 12942 | 0.030 |
Why?
|
| Quality of Life | 2 | 2022 | 13359 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 1999 | 1496 | 0.030 |
Why?
|
| Statistics as Topic | 2 | 2017 | 2358 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2006 | 4140 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2003 | 2409 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2006 | 1927 | 0.030 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 1997 | 187 | 0.030 |
Why?
|
| Prevalence | 5 | 2013 | 15702 | 0.030 |
Why?
|
| Presynaptic Terminals | 2 | 2009 | 302 | 0.030 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 1997 | 438 | 0.030 |
Why?
|
| Myocardium | 1 | 2008 | 4725 | 0.030 |
Why?
|
| Fluorescence | 1 | 2018 | 756 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2023 | 1808 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2018 | 587 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2021 | 2635 | 0.030 |
Why?
|
| Heart | 1 | 2008 | 4403 | 0.030 |
Why?
|
| Indole Alkaloids | 1 | 1994 | 23 | 0.030 |
Why?
|
| Plasmids | 1 | 2000 | 2265 | 0.030 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 1994 | 56 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2002 | 1349 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2018 | 901 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2010 | 9310 | 0.030 |
Why?
|
| Random Allocation | 2 | 2012 | 2392 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2024 | 1894 | 0.030 |
Why?
|
| Homozygote | 1 | 1999 | 1776 | 0.030 |
Why?
|
| Oncostatin M | 1 | 1994 | 42 | 0.030 |
Why?
|
| Ciliary Neurotrophic Factor | 1 | 1994 | 77 | 0.030 |
Why?
|
| Comorbidity | 3 | 2018 | 10507 | 0.030 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 1994 | 77 | 0.030 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2020 | 820 | 0.030 |
Why?
|
| Circadian Rhythm | 1 | 2006 | 2569 | 0.030 |
Why?
|
| Electric Stimulation | 3 | 2009 | 1734 | 0.030 |
Why?
|
| Patch-Clamp Techniques | 2 | 2007 | 925 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2022 | 2327 | 0.030 |
Why?
|
| Tomography, Emission-Computed | 1 | 1997 | 1122 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 20077 | 0.030 |
Why?
|
| Macrophages | 2 | 2017 | 5758 | 0.030 |
Why?
|
| Microscopy, Electron | 2 | 2009 | 2561 | 0.030 |
Why?
|
| Sympatholytics | 2 | 2003 | 82 | 0.030 |
Why?
|
| Staurosporine | 1 | 1994 | 242 | 0.030 |
Why?
|
| Cytokines | 3 | 2017 | 7373 | 0.030 |
Why?
|
| Heart Rate | 2 | 2008 | 4181 | 0.030 |
Why?
|
| T-Lymphocytes | 2 | 2001 | 10175 | 0.030 |
Why?
|
| Carbazoles | 1 | 1994 | 220 | 0.030 |
Why?
|
| Isoquinolines | 1 | 1994 | 352 | 0.030 |
Why?
|
| Homocysteine | 2 | 2007 | 637 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2004 | 4739 | 0.030 |
Why?
|
| Indicators and Reagents | 2 | 2004 | 460 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2002 | 2802 | 0.030 |
Why?
|
| Drosophila Proteins | 1 | 2002 | 1698 | 0.030 |
Why?
|
| Pilocarpine | 1 | 2012 | 64 | 0.030 |
Why?
|
| Mitochondria, Liver | 2 | 2003 | 190 | 0.030 |
Why?
|
| Citrus sinensis | 1 | 2012 | 14 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1997 | 1169 | 0.030 |
Why?
|
| Prognosis | 2 | 2010 | 29601 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2015 | 748 | 0.030 |
Why?
|
| Postmenopause | 2 | 2017 | 2511 | 0.030 |
Why?
|
| Jaw | 1 | 2012 | 93 | 0.030 |
Why?
|
| Flavones | 1 | 2012 | 68 | 0.020 |
Why?
|
| Mice, Congenic | 1 | 2012 | 97 | 0.020 |
Why?
|
| Flavanones | 1 | 2012 | 74 | 0.020 |
Why?
|
| Multivariate Analysis | 4 | 2009 | 12043 | 0.020 |
Why?
|
| Alleles | 1 | 2023 | 6861 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2020 | 2112 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2012 | 315 | 0.020 |
Why?
|
| Confidence Intervals | 2 | 2011 | 2925 | 0.020 |
Why?
|
| Flavonols | 1 | 2012 | 85 | 0.020 |
Why?
|
| Malus | 1 | 2012 | 50 | 0.020 |
Why?
|
| Models, Biological | 2 | 2005 | 9461 | 0.020 |
Why?
|
| Tocopherols | 1 | 2011 | 44 | 0.020 |
Why?
|
| Selegiline | 1 | 2011 | 32 | 0.020 |
Why?
|
| Nerve Growth Factors | 1 | 1994 | 564 | 0.020 |
Why?
|
| Papio | 2 | 2003 | 669 | 0.020 |
Why?
|
| 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone | 1 | 1991 | 7 | 0.020 |
Why?
|
| Risk Assessment | 6 | 2012 | 23974 | 0.020 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 1 | 1991 | 100 | 0.020 |
Why?
|
| 8-Bromo Cyclic Adenosine Monophosphate | 1 | 1991 | 73 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2015 | 1972 | 0.020 |
Why?
|
| Antipyretics | 1 | 2011 | 23 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 2 | 2009 | 2063 | 0.020 |
Why?
|
| Wound Healing | 1 | 2002 | 2802 | 0.020 |
Why?
|
| Nitroprusside | 1 | 1991 | 272 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2018 | 3601 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 2734 | 0.020 |
Why?
|
| Arsenic | 1 | 2014 | 362 | 0.020 |
Why?
|
| Alcoholic Beverages | 1 | 2012 | 264 | 0.020 |
Why?
|
| Prodrugs | 1 | 2012 | 261 | 0.020 |
Why?
|
| Tea | 1 | 2012 | 287 | 0.020 |
Why?
|
| Second Messenger Systems | 1 | 1991 | 202 | 0.020 |
Why?
|
| Protein Binding | 2 | 2005 | 9345 | 0.020 |
Why?
|
| International Cooperation | 1 | 2016 | 1422 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2023 | 3412 | 0.020 |
Why?
|
| Defecation | 1 | 2011 | 190 | 0.020 |
Why?
|
| Neural Stem Cells | 1 | 2017 | 887 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2023 | 8619 | 0.020 |
Why?
|
| Patient Selection | 1 | 2022 | 4237 | 0.020 |
Why?
|
| Synaptosomes | 1 | 2009 | 116 | 0.020 |
Why?
|
| Mitochondria | 1 | 2023 | 3619 | 0.020 |
Why?
|
| Lipids | 1 | 2020 | 3332 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2017 | 3965 | 0.020 |
Why?
|
| Adrenergic Fibers | 1 | 1989 | 21 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2001 | 3045 | 0.020 |
Why?
|
| Adenosine A1 Receptor Agonists | 1 | 2008 | 13 | 0.020 |
Why?
|
| Introns | 1 | 2011 | 968 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2011 | 590 | 0.020 |
Why?
|
| Apoptosis | 2 | 2001 | 9476 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2009 | 472 | 0.020 |
Why?
|
| Dyskinesias | 1 | 2009 | 79 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2024 | 3426 | 0.020 |
Why?
|
| Haplorhini | 1 | 2009 | 525 | 0.020 |
Why?
|
| Reference Values | 2 | 2006 | 4919 | 0.020 |
Why?
|
| Maternal Behavior | 1 | 2010 | 307 | 0.020 |
Why?
|
| Thalamus | 1 | 1994 | 1047 | 0.020 |
Why?
|
| Kidney | 1 | 2003 | 7044 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 2008 | 12966 | 0.020 |
Why?
|
| Structure-Activity Relationship | 2 | 2003 | 3074 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2017 | 4269 | 0.020 |
Why?
|
| Sleep | 1 | 2003 | 4764 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2009 | 518 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2009 | 550 | 0.020 |
Why?
|
| Inflammation | 1 | 2007 | 10759 | 0.020 |
Why?
|
| Benzazepines | 1 | 2009 | 310 | 0.020 |
Why?
|
| Nootropic Agents | 1 | 2008 | 157 | 0.020 |
Why?
|
| Lipolysis | 1 | 2008 | 211 | 0.020 |
Why?
|
| Wakefulness | 2 | 2005 | 1264 | 0.020 |
Why?
|
| Glucagon-Like Peptides | 1 | 1989 | 153 | 0.020 |
Why?
|
| Abdominal Fat | 1 | 2009 | 221 | 0.020 |
Why?
|
| Self Report | 1 | 2018 | 3727 | 0.020 |
Why?
|
| Matrix Metalloproteinases, Membrane-Associated | 1 | 2006 | 14 | 0.020 |
Why?
|
| Contraceptives, Oral | 1 | 2009 | 553 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1994 | 36401 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 1994 | 6126 | 0.020 |
Why?
|
| Thioacetamide | 1 | 2006 | 22 | 0.020 |
Why?
|
| Hydroxyproline | 1 | 2006 | 110 | 0.020 |
Why?
|
| Sleep Disorders, Circadian Rhythm | 1 | 2009 | 196 | 0.020 |
Why?
|
| Anthropometry | 1 | 2011 | 1338 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 1703 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2010 | 991 | 0.020 |
Why?
|
| Carbon Tetrachloride | 1 | 2006 | 72 | 0.020 |
Why?
|
| Alanine | 1 | 2009 | 609 | 0.020 |
Why?
|
| Cholinergic Agents | 1 | 2006 | 96 | 0.020 |
Why?
|
| Pregnancy | 3 | 2010 | 29869 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 1994 | 1248 | 0.020 |
Why?
|
| Serotonin Antagonists | 1 | 2006 | 144 | 0.020 |
Why?
|
| Vesicular Glutamate Transport Protein 1 | 1 | 2005 | 14 | 0.020 |
Why?
|
| Health Status | 2 | 2010 | 4076 | 0.020 |
Why?
|
| Bicuculline | 1 | 2005 | 96 | 0.020 |
Why?
|
| Phenylacetates | 1 | 2005 | 112 | 0.020 |
Why?
|
| Qa-SNARE Proteins | 1 | 2005 | 52 | 0.020 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2006 | 151 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2012 | 2256 | 0.020 |
Why?
|
| Synaptophysin | 1 | 2005 | 139 | 0.020 |
Why?
|
| GABA Antagonists | 1 | 2005 | 119 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 3882 | 0.020 |
Why?
|
| Amyloid beta-Peptides | 1 | 2019 | 3839 | 0.020 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2005 | 142 | 0.020 |
Why?
|
| Serine | 1 | 2009 | 830 | 0.020 |
Why?
|
| Maleimides | 1 | 2005 | 112 | 0.020 |
Why?
|
| Life Change Events | 1 | 2010 | 953 | 0.020 |
Why?
|
| Arginine | 1 | 2009 | 933 | 0.020 |
Why?
|
| Mood Disorders | 1 | 2012 | 1127 | 0.020 |
Why?
|
| Static Electricity | 1 | 2005 | 261 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2010 | 2278 | 0.010 |
Why?
|
| Neurotransmitter Agents | 1 | 1989 | 665 | 0.010 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2006 | 332 | 0.010 |
Why?
|
| Hormone Replacement Therapy | 1 | 2010 | 751 | 0.010 |
Why?
|
| Educational Status | 1 | 2012 | 2509 | 0.010 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2006 | 361 | 0.010 |
Why?
|
| RNA | 1 | 1994 | 2713 | 0.010 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2007 | 397 | 0.010 |
Why?
|
| Seasons | 1 | 2010 | 1518 | 0.010 |
Why?
|
| Molecular Conformation | 1 | 2005 | 544 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 2004 | 110 | 0.010 |
Why?
|
| Nitro Compounds | 1 | 2004 | 74 | 0.010 |
Why?
|
| Cysteine | 1 | 2009 | 891 | 0.010 |
Why?
|
| Piperazines | 1 | 1994 | 2521 | 0.010 |
Why?
|
| Boston | 2 | 2008 | 9313 | 0.010 |
Why?
|
| Tyrosine | 1 | 2008 | 1440 | 0.010 |
Why?
|
| Apomorphine | 1 | 2003 | 149 | 0.010 |
Why?
|
| Drug Administration Routes | 1 | 2003 | 150 | 0.010 |
Why?
|
| Body Constitution | 1 | 2004 | 273 | 0.010 |
Why?
|
| Nutrition Assessment | 1 | 2007 | 726 | 0.010 |
Why?
|
| Prostaglandin D2 | 1 | 2003 | 108 | 0.010 |
Why?
|
| Synucleins | 1 | 2003 | 108 | 0.010 |
Why?
|
| Mice, Neurologic Mutants | 1 | 2003 | 107 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2002 | 5672 | 0.010 |
Why?
|
| Population | 1 | 2003 | 141 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 2008 | 1515 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2004 | 531 | 0.010 |
Why?
|
| Aspirin | 2 | 2005 | 3127 | 0.010 |
Why?
|
| Adenosine-5'-(N-ethylcarboxamide) | 1 | 2002 | 15 | 0.010 |
Why?
|
| Photochemistry | 1 | 2003 | 239 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2012 | 2650 | 0.010 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2003 | 140 | 0.010 |
Why?
|
| Denervation | 1 | 2003 | 265 | 0.010 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2005 | 852 | 0.010 |
Why?
|
| Computational Biology | 2 | 2005 | 3509 | 0.010 |
Why?
|
| Biopsy | 1 | 1994 | 6763 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 2 | 2002 | 6188 | 0.010 |
Why?
|
| Linear Models | 1 | 2012 | 5866 | 0.010 |
Why?
|
| Glycine | 1 | 2005 | 661 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2000 | 6345 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 6473 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 2003 | 613 | 0.010 |
Why?
|
| Birth Weight | 1 | 2010 | 2101 | 0.010 |
Why?
|
| Receptors, AMPA | 1 | 2003 | 335 | 0.010 |
Why?
|
| Adolescent | 4 | 2016 | 88247 | 0.010 |
Why?
|
| Adipocytes | 1 | 2008 | 1187 | 0.010 |
Why?
|
| Narcotic Antagonists | 1 | 2006 | 585 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 1989 | 1650 | 0.010 |
Why?
|
| Macaca fascicularis | 1 | 2003 | 900 | 0.010 |
Why?
|
| Cell Transplantation | 1 | 2003 | 472 | 0.010 |
Why?
|
| Electroencephalography | 1 | 1997 | 6240 | 0.010 |
Why?
|
| Menopause | 1 | 2009 | 1645 | 0.010 |
Why?
|
| Maze Learning | 1 | 2003 | 482 | 0.010 |
Why?
|
| Young Adult | 3 | 2016 | 59191 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 2002 | 913 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 2812 | 0.010 |
Why?
|
| Transplantation Chimera | 1 | 2003 | 593 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 836 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2002 | 517 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2008 | 4010 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 748 | 0.010 |
Why?
|
| Aging | 1 | 1999 | 8700 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 3798 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 2000 | 422 | 0.010 |
Why?
|
| Administration, Topical | 1 | 2002 | 703 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2004 | 2261 | 0.010 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2003 | 370 | 0.010 |
Why?
|
| Energy Intake | 1 | 2008 | 2133 | 0.010 |
Why?
|
| Piperidines | 1 | 2008 | 1655 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 2001 | 619 | 0.010 |
Why?
|
| Ethanol | 1 | 2006 | 1320 | 0.010 |
Why?
|
| Research | 1 | 2008 | 1977 | 0.010 |
Why?
|
| Parity | 1 | 2003 | 924 | 0.010 |
Why?
|
| Sleep Stages | 1 | 2003 | 695 | 0.010 |
Why?
|
| Cytotoxins | 1 | 2000 | 153 | 0.010 |
Why?
|
| Methotrexate | 1 | 2006 | 1716 | 0.010 |
Why?
|
| Nutrition Surveys | 1 | 2007 | 1725 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2003 | 1878 | 0.010 |
Why?
|
| Chemokines | 1 | 2003 | 954 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2002 | 908 | 0.010 |
Why?
|
| Hepatocytes | 1 | 2006 | 1231 | 0.010 |
Why?
|
| Carbon Radioisotopes | 1 | 2000 | 561 | 0.010 |
Why?
|
| Metaplasia | 1 | 2000 | 324 | 0.010 |
Why?
|
| Toll-Like Receptors | 1 | 2002 | 575 | 0.010 |
Why?
|
| Weight Gain | 1 | 2009 | 2349 | 0.010 |
Why?
|
| Leucine | 1 | 2000 | 548 | 0.010 |
Why?
|
| Sports | 1 | 2005 | 705 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 6305 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 1991 | 3796 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2000 | 1085 | 0.010 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2002 | 578 | 0.010 |
Why?
|
| Family | 1 | 2009 | 3193 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 7805 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2005 | 2916 | 0.010 |
Why?
|
| Collagen | 1 | 2006 | 2634 | 0.010 |
Why?
|
| Electromyography | 1 | 2003 | 1392 | 0.010 |
Why?
|
| Transcription Factors | 1 | 1997 | 12116 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2000 | 1748 | 0.010 |
Why?
|
| Models, Animal | 1 | 2004 | 2108 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1989 | 13442 | 0.010 |
Why?
|
| Cytosol | 1 | 2000 | 886 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 3776 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 6074 | 0.010 |
Why?
|
| Endocytosis | 1 | 2000 | 955 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2005 | 2872 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2005 | 5433 | 0.010 |
Why?
|
| Adaptation, Physiological | 1 | 2002 | 1300 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2000 | 1171 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1997 | 15609 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2005 | 5780 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2002 | 3145 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1997 | 20556 | 0.010 |
Why?
|
| Massachusetts | 1 | 2006 | 8835 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 12420 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2003 | 2597 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2000 | 3730 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 4512 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2000 | 2546 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 4433 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 17630 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2002 | 3492 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2007 | 9417 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2005 | 5074 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2005 | 10429 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2005 | 7847 | 0.000 |
Why?
|
| Dihydroxyphenylalanine | 1 | 1988 | 74 | 0.000 |
Why?
|
| Neoplasm Proteins | 1 | 2000 | 3607 | 0.000 |
Why?
|
| Potassium | 1 | 1988 | 1311 | 0.000 |
Why?
|
| Evoked Potentials | 1 | 1988 | 1047 | 0.000 |
Why?
|